Here is the design of a clinical trial:

Official Title: Randomised Controlled Trial of Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Due to Enterobacteriaceae Showing Resistance to Third Generation Cephalosporins

Included conditions:
- Bacteremia

Study Armgroups:
- {'label': 'Temocillin', 'type': 'EXPERIMENTAL', 'description': 'Patients enrolled in this arm, will receive 2g each 8 hours of intravenous temocillin.', 'interventionNames': ['Drug: Temocillin']}
- {'label': 'Meropenem', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients enrolled in this arm, will receive 1g each 8 hours of intravenous meropenem.', 'interventionNames': ['Drug: Meropenem']}

Interventions:
- {'type': 'DRUG', 'name': 'Temocillin', 'description': 'The intervention of experimental arm will be Intravenous administration of temocillin.', 'armGroupLabels': ['Temocillin']}
- {'type': 'DRUG', 'name': 'Meropenem', 'description': 'The intervention of comparator arm will be intravenous administration of meropenem.', 'armGroupLabels': ['Meropenem']}

Primary Outcomes:
- {'measure': 'Number of participants with a "success" at the test of cure (TOC)', 'description': 'A success at the test of cure is the resolution of infection symptoms', 'timeFrame': 'Up to 7-10 days after the last day of antibiotic therapy'}
- {'measure': 'Survival at day 28', 'description': 'Number of patients who are alive', 'timeFrame': 'At day 28.'}
- {'measure': 'Number of patients who do not need to stop or change the assigned drug', 'description': 'Reasons for not change can be no adverse event, no perceived failure during treatment or no occurrence of a superimposed infection.\n\nParticipants who stop or change the assigned drug will not meet the primary outcome.', 'timeFrame': 'Up to 7-14 days after the last day of antibiotic therapy'}
- {'measure': 'Number of patients who do not need to prolong therapy beyond 14 days', 'description': 'Assigned treatment to be administered for less than 14 days', 'timeFrame': 'Up to 7-14 days after the last day of antibiotic therapy'}
- {'measure': 'Not recurrence until day 28', 'description': 'Recurrence is reappearance of symptoms with positive blood culture for the same microorganism.\n\nParticipants with recurrence will not meet the primary outcome.', 'timeFrame': 'At day 28.'}

Please estimate the sample size based on the assumption: 
80% power, 5% one-sided significance level, 5% missing patients, 1:1 assignment
Sample size
        We estimated an 85% success rate with meropenem and with temocillin. In order to reject the null hypothesis with 80% power and a 5% one-sided significance level for a 10% non-inferiority margin with a 1:1 assignment, with 5% of missing patients, a total of 167 patients in each study arm are needed (total, 334 patients).